Commenting on Misonix's financial and operating results, Michael A. McManus Jr., President and Chief Executive Officer, said, "We are pleased at the growth of our revenues and gross margins particularly with respect to our medical device products. We have started to see the benefit of the direct sales of our Neuroaspirator business both in increased revenue and margins. Our cost reduction efforts have lowered our total operating expenses by approximately $500,000 from the prior year six months results. We were able to achieve these cost reductions while increasing brand awareness of our medical devices through direct sales.
"Over the next couple of months we will be introducing the BoneScalpel™ into the Maxiofacial surgery market and the SonicOne® into the operating room for surgical debridement. Both products will be sold throughout the world exclusively by our own sales organization.
"We remain committed to our strategic vision and belief that increased medical device sales through our proprietary sales channels, a broader geographic reach, and development of new surgical applications and technology, will strengthen and grow the company over time."
Conference Call:Misonix management will host a conference call and webcast on Wednesday, February 9, 2011 at 4:30 pm to discuss second quarter results.
Shareholders and other interested parties may participate in the conference call by dialing (866)383-7989 (domestic) or (617) 597-5328 (international) and entering access code 69318379, a few minutes before the start of the call. A simultaneous webcast will be available via Misonix's website at
|SOURCE Misonix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved